How Analysts Rated Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Last Week?

January 13, 2018 - By Kurt Siggers

 How Analysts Rated Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Last Week?
Investors sentiment increased to 2.84 in Q3 2017. Its up 1.89, from 0.95 in 2017Q2. It improved, as 13 investors sold Spectrum Pharmaceuticals, Inc. shares while 19 reduced holdings. 38 funds opened positions while 53 raised stakes. 71.60 million shares or 29.39% more from 55.33 million shares in 2017Q2 were reported.
Bnp Paribas Arbitrage holds 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 39,970 shares. Profund Advsrs Ltd Liability Corporation invested in 14,030 shares or 0.01% of the stock. Miles Capital holds 16,005 shares or 0.13% of its portfolio. 74,774 were reported by Secor Capital Advsrs Lp. Wells Fargo And Mn has 949,290 shares. Invesco accumulated 393,459 shares. Millennium Mngmt Limited Co owns 222,359 shares. Moreover, Vantage Limited Liability has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 200 shares. Acadian Asset Ltd Liability Corp holds 2,525 shares. Blackrock owns 11.98 million shares for 0.01% of their portfolio. Clarivest Asset Mngmt Ltd Company stated it has 282,024 shares. Barclays Public Limited Company has 0.02% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Ubs Asset Mgmt Americas reported 40,332 shares. 13,639 are owned by Campbell Invest Adviser Ltd Llc. 59,945 are owned by Manufacturers Life Company The.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma has $32 highest and $8.25 lowest target. $19.46’s average target is 0.21% above currents $19.42 stock price. Spectrum Pharma had 11 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Friday, February 10 report. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has “Buy” rating given on Monday, October 9 by Jefferies. As per Thursday, August 27, the company rating was upgraded by Zacks. The firm has “Buy” rating given on Wednesday, August 16 by H.C. Wainwright. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, November 5. The firm earned “Outperform” rating on Friday, August 7 by RBC Capital Markets. The firm earned “Buy” rating on Wednesday, June 7 by Jefferies. Jefferies maintained Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rating on Thursday, August 24. Jefferies has “Buy” rating and $9.0 target. Below is a list of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) latest ratings and price target changes.

18/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $26 Initiates Coverage On
18/12/2017 Broker: FBR Capital Rating: Buy New Target: $26.0
24/10/2017 Broker: Guggenheim Rating: Buy New Target: $32 Initiates Coverage On
09/10/2017 Broker: Jefferies Rating: Buy Old Target: $13 New Target: $18 Maintain
24/08/2017 Broker: Jefferies Rating: Buy New Target: $9.0 Maintain
16/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $14 Reinitiate

The stock increased 0.62% or $0.12 during the last trading session, reaching $19.42. About 557,601 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 20.03% since January 13, 2017 and is downtrending. It has underperformed by 36.73% the S&P500.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.94 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

More news for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) were recently published by: Businesswire.com, which released: “Spectrum Pharmaceuticals Announces Leadership Changes” on December 17, 2017. Seekingalpha.com‘s article titled: “Spectrum Pharmaceuticals: Buy The Dip” and published on December 24, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: